SAN DIEGO, Sept. 05, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in
the discovery and development of immunology-based therapeutics, harnessing new pathway insights from human Physiocrine proteins, to
treat patients suffering from severe, rare immune-mediated diseases, as well as various cancers, today announced its participation
at two investor conferences in September:
- A fireside chat at the 2017 Wells Fargo Healthcare Conference in Boston on Wednesday, September 6,
at 8:30 a.m. Eastern Time.
- A presentation at Ladenburg Thalmann’s 2017 Healthcare Conference in New York City on Tuesday, September 26 at 11:30 a.m.
Eastern Time. This presentation will be webcast live through the "Investors" section of the aTyr Pharma website
at www.atyrpharma.com. An audio replay
will be available for at least 30 days following the initial presentation webcast.
About aTyr Pharma
aTyr Pharma is engaged in the discovery and clinical development of innovative medicines for patients using its knowledge of
Physiocrine biology, a newly discovered set of immunological and physiological pathways. To date, aTyr has generated three
innovative therapeutic programs with three different biologic modalities based on its knowledge of the Resokine pathway to treat
patients suffering from severe, rare immune-mediated diseases, as well as various cancers. The Resolaris and iMod.Fc programs are
agonists of the Resokine pathway designed to temper immune system engagement in diseases characterized by excessive immune cell
involvement. aTyr’s third program, ORCA, represents a novel, proprietary pathway in immuno-oncology that utilizes antibody
approaches to block the Resokine pathway and ‘release multiple brakes’ on the immune system in the tumor cell environment. aTyr has
built an intellectual property estate, to protect its pipeline, comprising over 220 issued patents or allowed patent applications
that are owned or exclusively licensed, including over 300 potential Physiocrine-based protein compositions. For more information,
please visit http://www.atyrpharma.com.
Contact: Mark Johnson Sr. Director, Investor Relations mjohnson@atyrpharma.com 858-223-1163
